High Growth Tech Stocks in South Korea for September 2024

The South Korea stock market has finished lower in six straight sessions, plunging more than 160 points or 6 percent along the way. The KOSPI now rests just above the 2,520-point plateau although it's expected to find traction on Wednesday. In this environment of volatility and mixed global forecasts, identifying high growth tech stocks that can weather market fluctuations becomes crucial for investors seeking robust returns.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	33.61%	52.05%	★★★★★★
IMLtd	21.80%	111.43%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
NEXON Games	29.64%	66.98%	★★★★★★
Park Systems	23.64%	35.66%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
UTI	114.97%	134.61%	★★★★★★

Click here to see the full list of 49 stocks from our KRX High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Medy-Tox (KOSDAQ:A086900)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Medy-Tox Inc. is a biopharmaceutical company based in South Korea with a market cap of ₩1.23 trillion.

Operations: Medy-Tox Inc. focuses on biotechnology, generating ₩246.25 billion in revenue from this segment. The company operates within the biopharmaceutical industry in South Korea.

Medy-Tox, a prominent player in South Korea's biotech sector, reported net income of ₩11.41 billion for Q2 2024, up from ₩8.57 billion the previous year. Despite negative sales figures, the company's earnings per share rose to ₩1,695 from ₩1,273. R&D expenses are significant, reflecting their commitment to innovation; with a forecasted revenue growth of 11.7% annually and earnings projected to grow by 62%, Medy-Tox shows strong potential in high-growth tech areas like AI-driven drug discovery and advanced biopharmaceuticals.

• Navigate through the intricacies of Medy-Tox with our comprehensive health report here.

• Review our historical performance report to gain insights into Medy-Tox's's past performance.

PharmaResearch (KOSDAQ:A214450)

Simply Wall St Growth Rating: ★★★★★☆

Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea and has a market cap of ₩1.95 billion.

Operations: PharmaResearch Co., Ltd. generates its revenue primarily from its pharmaceuticals segment, amounting to ₩296.59 billion. The company focuses on biopharmaceutical products and operates mainly within South Korea.

PharmaResearch is making significant strides in the biotech sector, with earnings growing by 63.2% over the past year, outpacing the industry average of 6.1%. The company's revenue is projected to grow at an impressive rate of 22.1% annually, surpassing the South Korean market's forecast of 10.4%. Notably, PharmaResearch has invested heavily in R&D, with expenses reflecting a strong commitment to innovation and future growth potential in advanced biopharmaceuticals and AI-driven drug discovery.

• Dive into the specifics of PharmaResearch here with our thorough health report.

• Evaluate PharmaResearch's historical performance by accessing our past performance report.

Lunit (KOSDAQ:A328130)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Lunit Inc. develops and provides AI-based software solutions for cancer screening, diagnosis, and treatment, with a market cap of ₩1.21 billion.

Operations: Lunit Inc. generates revenue by developing and providing AI-based software solutions focused on cancer screening, diagnosis, and treatment. The company has a market capitalization of ₩1.21 billion.

Lunit has demonstrated impressive growth, with revenue forecasted to increase by 51.8% annually, significantly outpacing the South Korean market's average of 10.4%. Despite being unprofitable currently, earnings are projected to grow at a robust rate of 104.9% per year, positioning the company for profitability within three years. Their R&D expenses reflect a strong commitment to innovation; recent advancements in AI-powered chest X-ray analysis software underscore their potential impact on global healthcare challenges like tuberculosis detection.

• Delve into the full analysis health report here for a deeper understanding of Lunit.

• Gain insights into Lunit's historical performance by reviewing our past performance report.

Next Steps

• Embark on your investment journey to our 49 KRX High Growth Tech and AI Stocks selection here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com